Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy.
Identifieur interne : 000D59 ( PubMed/Corpus ); précédent : 000D58; suivant : 000D60Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy.
Auteurs : A. Poujois ; M. Vidailhet ; J-M Trocello ; F. Bourdain ; B. Gaymard ; S. Rivaud-PéchouxSource :
- European journal of neurology [ 1468-1331 ] ; 2007.
English descriptors
- KwdEn :
- Aged, Amines (therapeutic use), Antiparkinson Agents (therapeutic use), Cyclohexanecarboxylic Acids (therapeutic use), Eye Movements (drug effects), Female, Humans, Male, Parkinson Disease (complications), Parkinson Disease (drug therapy), Severity of Illness Index, Supranuclear Palsy, Progressive (complications), Supranuclear Palsy, Progressive (drug therapy), gamma-Aminobutyric Acid (therapeutic use).
- MESH :
- chemical , therapeutic use : Amines, Antiparkinson Agents, Cyclohexanecarboxylic Acids, gamma-Aminobutyric Acid.
- complications : Parkinson Disease, Supranuclear Palsy, Progressive.
- drug effects : Eye Movements.
- drug therapy : Parkinson Disease, Supranuclear Palsy, Progressive.
- Aged, Female, Humans, Male, Severity of Illness Index.
Abstract
The efficacy of gabapentin on motor, oculomotor and frontal lobe symptoms was evaluated in patients with progressive supranuclear palsy (PSP) in a pilot study. Fourteen patients were included and seven of them received gabapentin. Clinical evaluation and horizontal eye movement recordings were performed at inclusion and 5-weeks later. Motor score and saccade latency in the visually guided saccade (VGS) task were identical in the two groups. However, the error rate in the antisaccade task was significantly decreased in the gabapentin group. This preliminary study shows that gabapentin improves reflexive saccade inhibition in patients with PSP but does not improve the latency of VGSs.
DOI: 10.1111/j.1468-1331.2007.01687.x
PubMed: 17718702
Links to Exploration step
pubmed:17718702Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy.</title><author><name sortKey="Poujois, A" sort="Poujois, A" uniqKey="Poujois A" first="A" last="Poujois">A. Poujois</name><affiliation><nlm:affiliation>Service de Neurologie, CHU Saint-Etienne, Saint-Etienne, France. aurelia.poujois@chu-st-etienne.fr</nlm:affiliation></affiliation></author><author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M" last="Vidailhet">M. Vidailhet</name></author><author><name sortKey="Trocello, J M" sort="Trocello, J M" uniqKey="Trocello J" first="J-M" last="Trocello">J-M Trocello</name></author><author><name sortKey="Bourdain, F" sort="Bourdain, F" uniqKey="Bourdain F" first="F" last="Bourdain">F. Bourdain</name></author><author><name sortKey="Gaymard, B" sort="Gaymard, B" uniqKey="Gaymard B" first="B" last="Gaymard">B. Gaymard</name></author><author><name sortKey="Rivaud Pechoux, S" sort="Rivaud Pechoux, S" uniqKey="Rivaud Pechoux S" first="S" last="Rivaud-Péchoux">S. Rivaud-Péchoux</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17718702</idno><idno type="pmid">17718702</idno><idno type="doi">10.1111/j.1468-1331.2007.01687.x</idno><idno type="wicri:Area/PubMed/Corpus">000D59</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000D59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy.</title><author><name sortKey="Poujois, A" sort="Poujois, A" uniqKey="Poujois A" first="A" last="Poujois">A. Poujois</name><affiliation><nlm:affiliation>Service de Neurologie, CHU Saint-Etienne, Saint-Etienne, France. aurelia.poujois@chu-st-etienne.fr</nlm:affiliation></affiliation></author><author><name sortKey="Vidailhet, M" sort="Vidailhet, M" uniqKey="Vidailhet M" first="M" last="Vidailhet">M. Vidailhet</name></author><author><name sortKey="Trocello, J M" sort="Trocello, J M" uniqKey="Trocello J" first="J-M" last="Trocello">J-M Trocello</name></author><author><name sortKey="Bourdain, F" sort="Bourdain, F" uniqKey="Bourdain F" first="F" last="Bourdain">F. Bourdain</name></author><author><name sortKey="Gaymard, B" sort="Gaymard, B" uniqKey="Gaymard B" first="B" last="Gaymard">B. Gaymard</name></author><author><name sortKey="Rivaud Pechoux, S" sort="Rivaud Pechoux, S" uniqKey="Rivaud Pechoux S" first="S" last="Rivaud-Péchoux">S. Rivaud-Péchoux</name></author></analytic><series><title level="j">European journal of neurology</title><idno type="eISSN">1468-1331</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Amines (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Cyclohexanecarboxylic Acids (therapeutic use)</term><term>Eye Movements (drug effects)</term><term>Female</term><term>Humans</term><term>Male</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Severity of Illness Index</term><term>Supranuclear Palsy, Progressive (complications)</term><term>Supranuclear Palsy, Progressive (drug therapy)</term><term>gamma-Aminobutyric Acid (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Amines</term><term>Antiparkinson Agents</term><term>Cyclohexanecarboxylic Acids</term><term>gamma-Aminobutyric Acid</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Eye Movements</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The efficacy of gabapentin on motor, oculomotor and frontal lobe symptoms was evaluated in patients with progressive supranuclear palsy (PSP) in a pilot study. Fourteen patients were included and seven of them received gabapentin. Clinical evaluation and horizontal eye movement recordings were performed at inclusion and 5-weeks later. Motor score and saccade latency in the visually guided saccade (VGS) task were identical in the two groups. However, the error rate in the antisaccade task was significantly decreased in the gabapentin group. This preliminary study shows that gabapentin improves reflexive saccade inhibition in patients with PSP but does not improve the latency of VGSs.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17718702</PMID><DateCreated><Year>2007</Year><Month>08</Month><Day>27</Day></DateCreated><DateCompleted><Year>2007</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>9</Issue><PubDate><Year>2007</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur. J. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy.</ArticleTitle><Pagination><MedlinePgn>1060-2</MedlinePgn></Pagination><Abstract><AbstractText>The efficacy of gabapentin on motor, oculomotor and frontal lobe symptoms was evaluated in patients with progressive supranuclear palsy (PSP) in a pilot study. Fourteen patients were included and seven of them received gabapentin. Clinical evaluation and horizontal eye movement recordings were performed at inclusion and 5-weeks later. Motor score and saccade latency in the visually guided saccade (VGS) task were identical in the two groups. However, the error rate in the antisaccade task was significantly decreased in the gabapentin group. This preliminary study shows that gabapentin improves reflexive saccade inhibition in patients with PSP but does not improve the latency of VGSs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Poujois</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Service de Neurologie, CHU Saint-Etienne, Saint-Etienne, France. aurelia.poujois@chu-st-etienne.fr</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidailhet</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Trocello</LastName><ForeName>J-M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Bourdain</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Gaymard</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Rivaud-Péchoux</LastName><ForeName>S</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000588">Amines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003509">Cyclohexanecarboxylic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>56-12-2</RegistryNumber><NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>6CW7F3G59X</RegistryNumber><NameOfSubstance UI="C040029">gabapentin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000588" MajorTopicYN="N">Amines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003509" MajorTopicYN="N">Cyclohexanecarboxylic Acids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005133" MajorTopicYN="N">Eye Movements</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013494" MajorTopicYN="N">Supranuclear Palsy, Progressive</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17718702</ArticleId><ArticleId IdType="pii">ENE1687</ArticleId><ArticleId IdType="doi">10.1111/j.1468-1331.2007.01687.x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000D59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17718702
|texte= Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17718702" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |